Real-Time Evaluation of Emerging Treatments for Suicide Risk
自杀风险新兴治疗方法的实时评估
基本信息
- 批准号:10663086
- 负责人:
- 金额:$ 31.81万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2019
- 资助国家:美国
- 起止时间:2019-09-23 至 2024-12-31
- 项目状态:已结题
- 来源:
- 关键词:Adverse effectsBindingCessation of lifeClinical ResearchClinical TrialsCollectionComplexCycloserineDataDevelopmentEvaluationFeeling suicidalGenerationsGleevecGlutamate ReceptorHealth systemHeterogeneityHospitalizationInfusion proceduresIntravenousKetamineLibrariesLicensingLicensureMental DepressionMental HealthMethodsOutcomeOutpatientsOxycodonePatient Outcomes AssessmentsPatient SelectionPatientsPatternPharmaceutical PreparationsPhenotypePhysician ExecutivesProbabilityProviderRecording of previous eventsRecreationResearchRisk FactorsRisk ReductionRisk Reduction BehaviorSequential TreatmentSeriesSuicide attemptTimeTranslatingWorkanalytical methoddata infrastructuredepressive symptomsdesigninnovationinterestmachine learning modeloff-label usepractice-based research networkpsychotic symptomspublic health prioritiesreduce symptomssuicidal behaviorsuicidal morbiditysuicidal risktreatment durationtreatment effecttreatment risktreatment-resistant depression
项目摘要
Reducing risk of suicidal behavior is an urgent public health priority. Evidence that intravenous ketamine
infusion could rapidly reduce symptoms of depression and suicidal ideation led to a series of small clinical
trials, as well as increasing off-label use for treatment of severe depression. Findings regarding effects of
ketamine infusion on suicidal ideation have inspired development of new medications designed to mimic
ketamine's glutamate receptor modulator activity. Two of those products (intranasal esketamine and a
sequential treatment of ketamine infusion followed by lurasidone plus d-cycloserine) have been designated by
the FDA as potential breakthrough treatments, with rapid approval expected. Clinical trials completed prior to
licensure will likely demonstrate that these new products (and similar products to follow) rapidly reduce
symptoms of depression and suicidal ideation – leading to approval for those specific indications. Pre-approval
trials, however, will not address questions of greatest interest to patients, providers, and health systems: Will
short-term reductions in suicidal ideation actually translate to reduced risk of suicidal behavior? Enthusiasm
regarding the potential benefits of new ketamine-like drugs is tempered by concerns regarding adverse effects,
tolerance/rebound, and potential for misuse. Intravenous ketamine infusion can precipitate dissociative or
psychotic symptoms, and ketamine has a long history of recreational misuse. During our discussions with
health system leaders regarding this proposed research, one medical director pointed out, “Esketamine could
be the next Gleevec or the next Oxycontin. We had better find out which.”
We propose to use innovative methods to rapidly evaluate the effect of these anticipated new
treatments on risk of suicidal behavior among outpatients with treatment-resistant depression. This work will
take advantage of unique capabilities of our network, including comprehensive longitudinal data infrastructure,
routine collection of patient-reported outcome data, an extensive library of computable EHR phenotypes
regarding suicidal behavior risk factors and outcomes, machine-learning models to accurately predict suicidal
behavior, and analytic methods for causal inference for rare exposures and outcomes. The proposed research
will use data from three MHRN health systems to:
1) Rapidly evaluate patterns of use of newly approved therapies for treatment-resistant depression
2) Extract comprehensive predictor and outcome data regarding patients receiving and not receiving
emerging treatments with potential to reduce risk of suicidal behavior
3) Develop and implement variable selection approaches for weighted propensity score analyses
4) Use these data and methods to evaluate impact of emerging treatments on risk of suicide death, suicide
attempt, or psychiatric hospitalization within 90 days of a treatment decision.
5) Examine heterogeneity of treatment effects according to pre-treatment risk of suicidal behavior
降低自杀行为的风险是一项紧迫的公共卫生优先事项。有证据表明静脉注射氯胺酮
输注可以迅速减轻抑郁症状和自杀意念,导致一系列小的临床
试验,以及增加用于治疗严重抑郁症的标签外使用。关于影响的调查结果
氯胺酮注射对自杀意念的作用激发了新药物的开发,
氯胺酮的谷氨酸受体调节剂活性。其中两种产品(鼻内艾司氯胺酮和
氯胺酮输注,然后鲁拉西酮+d-环丝氨酸序贯治疗)已被指定为
作为潜在的突破性治疗,预计将迅速获得批准。之前完成的临床试验
许可证可能会证明这些新产品(以及随后的类似产品)迅速减少
抑郁症和自杀意念的症状-导致批准这些特定的适应症。前置审批
然而,试验不会解决患者、提供者和卫生系统最感兴趣的问题:
短期内减少自杀意念真的会降低自杀行为的风险吗?热情
关于新的氯胺酮样药物的潜在益处的担忧被关于副作用的担忧所缓和,
公差/回弹和误用的可能性。静脉注射氯胺酮可导致游离或
精神病症状,而克他命有很长的娱乐性滥用史在我们与
关于这项拟议的研究,一位医学主任指出,"艾司氯胺酮可以
成为下一个格列卫或者下一个奥施康定我们最好弄清楚是哪一个。"
我们建议使用创新的方法来快速评估这些预期的新的影响,
难治性抑郁症门诊患者自杀行为风险的治疗这项工作将
利用我们网络的独特功能,包括全面的纵向数据基础设施,
常规收集患者报告的结果数据,一个广泛的可计算EHR表型库
关于自杀行为的风险因素和结果,机器学习模型可以准确预测自杀
行为和分析方法的因果推理罕见的曝光和结果。拟议研究
将使用来自三个MHRN卫生系统的数据:
1)快速评估新批准的难治性抑郁症治疗方法的使用模式
2)提取关于接受和未接受治疗的患者的综合预测因子和结局数据
有可能降低自杀行为风险的新兴治疗方法
3)制定和实施加权倾向得分分析的变量选择方法
4)使用这些数据和方法来评估新兴治疗对自杀死亡风险的影响,
在决定治疗后90天内尝试或精神病住院治疗。
5)根据治疗前自杀行为风险检查治疗效果的异质性
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
GREGORY E. SIMON其他文献
GREGORY E. SIMON的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('GREGORY E. SIMON', 18)}}的其他基金
Real-Time Evaluation of Emerging Treatments for Suicide Risk
自杀风险新兴治疗方法的实时评估
- 批准号:
10197806 - 财政年份:2019
- 资助金额:
$ 31.81万 - 项目类别:
Whose Depression Are We Measuring?: Considering the role of place on Black women’s depression outcomes
我们在测量谁的抑郁症?:考虑地点对黑人女性抑郁症结果的作用
- 批准号:
10818149 - 财政年份:2019
- 资助金额:
$ 31.81万 - 项目类别:
Real-Time Evaluation of Emerging Treatments for Suicide Risk
自杀风险新兴治疗方法的实时评估
- 批准号:
10021735 - 财政年份:2019
- 资助金额:
$ 31.81万 - 项目类别:
相似国自然基金
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
- 批准号:32170319
- 批准年份:2021
- 资助金额:58.00 万元
- 项目类别:面上项目
帽结合蛋白(cap binding protein)调控乙烯信号转导的分子机制
- 批准号:
- 批准年份:2021
- 资助金额:58 万元
- 项目类别:
ID1 (Inhibitor of DNA binding 1) 在口蹄疫病毒感染中作用机制的研究
- 批准号:31672538
- 批准年份:2016
- 资助金额:62.0 万元
- 项目类别:面上项目
番茄EIN3-binding F-box蛋白2超表达诱导单性结实和果实成熟异常的机制研究
- 批准号:31372080
- 批准年份:2013
- 资助金额:80.0 万元
- 项目类别:面上项目
P53 binding protein 1 调控乳腺癌进展转移及化疗敏感性的机制研究
- 批准号:81172529
- 批准年份:2011
- 资助金额:58.0 万元
- 项目类别:面上项目
DBP(Vitamin D Binding Protein)在多发性硬化中的作用和相关机制的蛋白质组学研究
- 批准号:81070952
- 批准年份:2010
- 资助金额:35.0 万元
- 项目类别:面上项目
研究EB1(End-Binding protein 1)的癌基因特性及作用机制
- 批准号:30672361
- 批准年份:2006
- 资助金额:24.0 万元
- 项目类别:面上项目
相似海外基金
Collaborative Research: NSF-BSF: How cell adhesion molecules control neuronal circuit wiring: Binding affinities, binding availability and sub-cellular localization
合作研究:NSF-BSF:细胞粘附分子如何控制神经元电路布线:结合亲和力、结合可用性和亚细胞定位
- 批准号:
2321481 - 财政年份:2024
- 资助金额:
$ 31.81万 - 项目类别:
Continuing Grant
Collaborative Research: NSF-BSF: How cell adhesion molecules control neuronal circuit wiring: Binding affinities, binding availability and sub-cellular localization
合作研究:NSF-BSF:细胞粘附分子如何控制神经元电路布线:结合亲和力、结合可用性和亚细胞定位
- 批准号:
2321480 - 财政年份:2024
- 资助金额:
$ 31.81万 - 项目类别:
Continuing Grant
Alkane transformations through binding to metals
通过与金属结合进行烷烃转化
- 批准号:
DP240103289 - 财政年份:2024
- 资助金额:
$ 31.81万 - 项目类别:
Discovery Projects
NPBactID - Differential binding of peptoid functionalized nanoparticles to bacteria for identifying specific strains
NPBactID - 类肽功能化纳米粒子与细菌的差异结合,用于识别特定菌株
- 批准号:
EP/Y029542/1 - 财政年份:2024
- 资助金额:
$ 31.81万 - 项目类别:
Fellowship
Conformations of musk odorants and their binding to human musk receptors
麝香气味剂的构象及其与人类麝香受体的结合
- 批准号:
EP/X039420/1 - 财政年份:2024
- 资助金额:
$ 31.81万 - 项目类别:
Research Grant
Postdoctoral Fellowship: OPP-PRF: Understanding the Role of Specific Iron-binding Organic Ligands in Governing Iron Biogeochemistry in the Southern Ocean
博士后奖学金:OPP-PRF:了解特定铁结合有机配体在控制南大洋铁生物地球化学中的作用
- 批准号:
2317664 - 财政年份:2024
- 资助金额:
$ 31.81万 - 项目类别:
Standard Grant
I-Corps: Translation Potential of Real-time, Ultrasensitive Electrical Transduction of Biological Binding Events for Pathogen and Disease Detection
I-Corps:生物结合事件的实时、超灵敏电转导在病原体和疾病检测中的转化潜力
- 批准号:
2419915 - 财政年份:2024
- 资助金额:
$ 31.81万 - 项目类别:
Standard Grant
The roles of a universally conserved DNA-and RNA-binding domain in controlling MRSA virulence and antibiotic resistance
普遍保守的 DNA 和 RNA 结合域在控制 MRSA 毒力和抗生素耐药性中的作用
- 批准号:
MR/Y013131/1 - 财政年份:2024
- 资助金额:
$ 31.81万 - 项目类别:
Research Grant
CRII: OAC: Development of a modular framework for the modeling of peptide and protein binding to membranes
CRII:OAC:开发用于模拟肽和蛋白质与膜结合的模块化框架
- 批准号:
2347997 - 财政年份:2024
- 资助金额:
$ 31.81万 - 项目类别:
Standard Grant
How lipid binding proteins shape the activity of nuclear hormone receptors
脂质结合蛋白如何影响核激素受体的活性
- 批准号:
DP240103141 - 财政年份:2024
- 资助金额:
$ 31.81万 - 项目类别:
Discovery Projects














{{item.name}}会员




